GSK-Birmingham Tissue Collaborative (GB-TC)
Research type
Research Study
Full title
Use of Tissue from Lung Resections to Investigate Molecular and Functional Mechanisms of Human Lung Disease
IRAS ID
212537
Contact name
David Thickett
Contact email
Sponsor organisation
GlaxoSmithKline R&D
Duration of Study in the UK
1 years, 11 months, 28 days
Research summary
\nLung diseases cause pain, breathlessness and can prevent sufferers from carrying out everyday activities. Several lung diseases, including lung cancer, require surgical removal of lung tissue as part of treatment. We would approach patients who are scheduled to undergo thoracic surgery or lung transplantation to remove diseased lung tissue as part of their treatment plan, and ask if they would consent to us performing research on the removed lung tissue, which would normally just be destroyed. We would also ask to take a blood sample to compare the findings in the lung tissue and blood, although this may not always be collected. A number of diseases will be studied and the lung tissue will be used in a number of different laboratory studies. The lung tissue will be used to improve our understanding of lung disease which may then lead to the development of new treatments.\n\nThe study will collect surplus Respiratory tissue from elective surgery and lung transplantation at Birmingham Hospitals. Tissue will be used in various projects at GSK designed to identify and validate drug targets, to investigate the mode of action and efficacy of potential new drug by in vitro assays of biomarkers of disease.\n
REC name
South West - Cornwall & Plymouth Research Ethics Committee
REC reference
17/SW/0069
Date of REC Opinion
28 Mar 2017
REC opinion
Further Information Favourable Opinion